Results 11 to 20 of about 60,986 (304)
Focus on Adoptive T Cell Transfer Trials in Melanoma [PDF]
Clinical and Developmental Immunology, 2010 Adoptive Cell Transfer (ACT) of Tumor-Infiltrating Lymphocytes (TIL) in combination with lymphodepletion has proven to be an effective treatment for metastatic melanoma patients, with an objective response rate in 50%–70% of the patients.
Liat Hershkovitz +3 more
doaj +4 more sources
Adoptive Transfer of Allogeneic Antigen-Specific T Cells [PDF]
Biology of Blood and Marrow Transplantation, 2006 Animal models and human studies of allogeneic hematopoietic cell transplantation (HCT) demonstrate that immunologic nonidentity between donor and recipient is responsible for a graft versus leukemia (GVL) effect that contributes to complete tumor eradication.
Stanley R. Riddell +4 more
openalex +3 more sources
Adoptive Cell Transfer Therapy [PDF]
Seminars in Oncology, 2007 Adoptive cell transfer therapy has developed into a potent and effective treatment for patients with metastatic melanoma. Current application of this therapy relies on the ex vivo generation of highly active, highly avid tumor-reactive lymphocyte cultures from endogenous tumor infiltrating lymphocytes or on the genetic engineering of cells using ...
Steven A. Rosenberg, Mark E. Dudley
openaire +2 more sources
High-affinity T cell receptors for adoptive cell transfer. [PDF]
J Clin Invest, 2019 Adoptive cell transfer (ACT) of engineered T cell receptors (TCRs) for cancer immunotherapy has evolved from simple gene transfer of isolated TCRs to various affinity enhancement techniques that overcome limitations imposed by central and peripheral tolerance on TCR affinity. In the current issue of the JCI, Poncette et al.
Isser A, Schneck JP.
europepmc +5 more sources
Adoptive Transfer of Memory B Cells [PDF]
BIO-PROTOCOL, 2015 The adoptive transfer of antigen-specific B cells into mice that cannot recognize that specific antigen has two main advantages. The first is determining exactly when the B cells were transferred and exposed to antigen. The second is that all B cells that can bind that antigen are the ones that were transferred; no new antigen-specific B cells will ...
Mark J. Shlomchik +1 more
openaire +4 more sources
Treatment of lymphoma with adoptively transferred T cells [PDF]
Expert Opinion on Biological Therapy, 2009 Chemotherapy-resistant lymphomas can be cured with allogeneic hematopoietic cell transplantation, demonstrating the susceptibility of these tumors to T cell mediated immune responses. However, high rates of transplant-related morbidity and mortality limit this approach.
Brian G. Till, Oliver W. Press
openaire +3 more sources
Phenotype and Hierarchy of Two Transgenic T Cell Lines Targeting the Respiratory Syncytial Virus KdM282-90 Epitope Is Transfer Dose-Dependent. [PDF]
PLoS ONE, 2016 In this study, we compared two lines of transgenic CD8+ T cells specific for the same KdM282-90 epitope of respiratory syncytial virus in the CB6F1 hybrid mouse model. Here we found that these two transgenic lines had similar in vivo abilities to control
Kaitlyn M Morabito +3 more
doaj +1 more source
Adoptive T-Cell Transfer to Treat Lymphangioleiomyomatosis
American Journal of Respiratory Cell and Molecular Biology, 2020 Patients with lymphangioleiomyomatosis (LAM) develop pulmonary cysts associated with neoplastic, smooth muscle-like cells that feature neuroendocrine cell markers. The disease preferentially affects premenopausal women. Existing therapeutics do not cure LAM.
Fei Han +10 more
openaire +3 more sources
Adoptive Cell Transfer in the Treatment of Metastatic Melanoma [PDF]
Journal of Investigative Dermatology, 2009 Adoptive cell therapy (ACT) for metastatic cancer is the focus of considerable research effort. Rosenberg's laboratory demonstrated a 50% response rate in stage IV melanoma patients treated with in vitro expanded tumor-infiltrating lymphocytes (TILs) and high-dose IL-2 administered after nonmyeloablative conditioning (Dudley et al., 2002a).
Straten, Per thor, Becker, Jürgen C
openaire +4 more sources
Adoptive Transfer of Regulatory Immune Cells in Organ Transplantation [PDF]
Frontiers in Immunology, 2021 Chronic graft rejection remains a significant barrier to solid organ transplantation as a treatment for end-organ failure. Patients receiving organ transplants typically require systemic immunosuppression in the form of pharmacological immunosuppressants for the duration of their lives, leaving these patients vulnerable to opportunistic infections ...
Carl Atkinson +2 more
openaire +3 more sources